so, we want kisqali.iving longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or br

so, we want kisqali.ing longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or brea

so, we want kisqali.onger is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor about living

so, we want kisqali.ing longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more t

so, we want kisqali. living longer is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor abou

so, we want kisqali.g longer is possible and proven with kisqali when taken with fulvestrant or aonlome inhibir in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grap

so, we want kisqali.s possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more time. we aske

so, we want kisqali. proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefrui

so, we want kisqali.ulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not app

so, we want kisqali.er is possible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. ask your doctor about living lon

so, we want kisqali.trant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved

so, we want kisqali.nd proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefr

so, we want kisqali.with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during

so, we want kisqali.s possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. a

so, we want kisqali. is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding.

so, we want kisqali.ble and proven with kisqali nsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali

so, we want kisqali.ing longer is possible and proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or brea

so, we want kisqali.h fulvestrant or a nonsteroidal aromatase inhibitor in hr+, her2- metastatic breast cancer. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not

so, we want kisqali.nd proven with kisqali when taken with fulvestrant or a nonsteroidal aromatase inhibitor in hr+, . r. kisqali is approved for both pre- and postmenopausal women, and has extended lives in multiple clinical trials. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor or fulvestrant alone. kisqali can cause lung problems, or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash, are or plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqa

so, we want kisqali.ssible and proven with kisqali when taken with a nonsteroidal aromatase inhibitor in premenopausal women with hr+, her2- metastatic breast cancer. kisqali is a pill that's significantly more effective at delaying disease progression versus a nonsteroidal aromatase inhibitor alone. kisqali can cause lung problems or an abnormal heartbeat, which can lead to death. it can cause serious skin reactions, liver problems, and low white blood cell counts that may result in severe infections. tell your doctor right away if you have new or worsening symptoms, including breathing problems, cough, chest pain, a change in your heartbeat, dizziness, yellowing of the skin or eyes, dark urine, tiredness, loss of appetite, abdomen pain, bleeding, bruising, fever, chills, or other symptoms of an infection, a severe or worsening rash or are plan to become pregnant, or breastfeeding. avoid grapefruit during treatment. kisqali is not approved for use with tamoxifen. it's our time. for more time. we asked fo